Загрузка видео...

Не удалось загрузить видео

На главную

microdosing

12,528 просмотров • 1 месяц назад •via X (Twitter)

Комментарии: 3

Фото профиля krendo
krendo1 месяц назад

Best character ever

Фото профиля Triplekang
Triplekang1 месяц назад

L!!!M!!!A!!!O!!!!

Фото профиля fansuki
fansuki1 месяц назад

love brian but he's always caught at the scene 😭

Похожие видео

Is AxonDAO's Psylosis, the First of Its Kind? Psylosis is one of the pioneering DeSci initiatives in the US integrating AI, blockchain, and IRB-approved ethical protocols. This ensures the process and data security meet the highest standards for safety, privacy, and data integrity. Did you know that from 1955 to 2021, there have only been 19 studies on microdosing psychedelics, with an average of 22 participants per study. There have been no (0) known clinical trials combining microdosing psilocybin with voice AI analysis. Microdosing Research: Most studies focus on full (Macro) doses due to regulatory preferences for larger, measurable impacts. Voice AI Technology: AI-driven voice analysis forl health is new and experimental in psychedelics research. Pioneering Efforts: Psylosis bridges traditional methods with innovative AI and DeSci approaches. Biometric data provided by your voice for Psylosis, into CureOS is an objective, quantifiable measurement of psilocybin's effects, complementing subjective reports. This multimodal approach improves understanding of its impact on the brain and body, advancing safe and effective therapies. Psilocybin, the active ingredient in magic mushrooms, has been increasingly studied. By 2021, 13 phase II trials worldwide examined its use (in full doses) for treating depression. These studies reflect rising interest in its therapeutic potential. However, this field is still emerging. Ongoing trials are needed to better understand psilocybin's safety and efficacy across medical conditions, and proper legal jurisdictions. To sign up for the Psylosis Project, updates, and its commitment to ethical research practices, visit our site axondao(dot)io

AxonDAO

20,317 просмотров • 1 год назад

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

Metabolic Mind

20,561 просмотров • 1 год назад